ArticleNature communications2021
Synthetic hydrogel nanoparticles for sepsis therapy.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 75 citations in OpenAlex.
- Multimodal hybrid nanozymes with antioxidant catalytic and antibiotic-free antibacterial activities for enhanced multi-target sepsis therapy.Cell reports. Medicine · 2026Article
- A one-shot approach for serum vancomycin assessment using fluorescence-based molecularly imprinted polymer nanoparticles.Mikrochimica acta · 2026Article
- Decoy Nanoparticles and Protein Corona Modulation: A Novel Frontier in Sepsis Treatment.International journal of nanomedicine · 2026Review
- The Role of Histone Modifications in Acute Lung Injury: Molecular Mechanisms and Potential of Traditional Chinese Medicine Treatment.Journal of inflammation research · 2026Review
- Nanogels with volume phase transition for biomedical applications.Nature communications · 2025Review
- Research advances on the role of programmed endothelial cell death in sepsis.Cell death discovery · 2025Review
- Nanomaterial-based encapsulation of biochemicals for targeted sepsis therapy.Materials today. Bio · 2025Review
- Lipid nanoparticles fromMolecular therapy. Methods & clinical development · 2025Article
- Review
- Noninvasive Vagus Nerve Electrical Stimulation for Immune Modulation in Sepsis Therapy.Journal of the American Chemical Society · 2025Article
- Polylysine-based copolymer self-assemblies featuring acidity-activated structural transformation perceives and relieves sepsis.Regenerative biomaterials · 2025Article
- Internal-External Homologous Drug-Loaded Exosome-Like Nanovesicles Released from Semi-IPN Hydrogel Enhancing Wound Healing of Chemoradiotherapy-Induced Oral Mucositis.International journal of nanomedicine · 2025Article
- Frontier and hot topics in the application of hydrogel in the biomedical field: a bibliometric analysis based on CiteSpace.Journal of biological engineering · 2024Article
- Applications of Hydrogels in Osteoarthritis Treatment.Biomedicines · 2024Review
- Emerging therapeutic strategies targeting extracellular histones for critical and inflammatory diseases: an updated narrative review.Frontiers in immunology · 2024Review
- Hydrogel Loaded with Components for Therapeutic Applications in Hypertrophic Scars and Keloids.International journal of nanomedicine · 2024Review
- Design of an Anti-HMGB1 Synthetic Antibody forJournal of the American Chemical Society · 2023Article
- In Situ Neutralization and Detoxification of LPS to Attenuate Hyperinflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Validation of circulating histone detection by mass spectrometry for early diagnosis, prognosis, and management of critically ill septic patients.Journal of translational medicine · 2023Article
- GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis.Experimental hematology & oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening condition caused by the extreme release of inflammatory mediators into the blood in response to infection (e.g., bacterial infection, COVID-19), resulting in the dysfunction of multiple organs. Currently, there is no direct treatment for sepsis. Here we report an abiotic hydrogel nanoparticle (HNP) as a potential therapeutic agent for late-stage sepsis. The HNP captures and neutralizes all variants of histones, a major inflammatory mediator released during sepsis. The highly optimized HNP has high capacity and long-term circulation capability for the selective sequestration and neutralization of histones. Intravenous injection of the HNP protects mice against a lethal dose of histones through the inhibition of platelet aggregation and migration into the lungs. In vivo administration in murine sepsis model mice results in near complete survival. These results establish the potential for synthetic, nonbiological polymer hydrogel sequestrants as a new intervention strategy for sepsis therapy and adds to our understanding of the importance of histones to this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.